Regeneron’s Bispecific Antibody Obtains EC Nod for Lymphoma
ZacksREGN’s oncology portfolio gets a boost with the approval of odronextamab for treating follicular lymphoma and diffuse large B-cell lymphoma (DLBCL).
REGN’s oncology portfolio gets a boost with the approval of odronextamab for treating follicular lymphoma and diffuse large B-cell lymphoma (DLBCL).